Evidence map›Paper›PMID 19482777›Full record

ReviewJournal of molecular cell biology2009

How diverse--CD4 effector T cells and their functions.

Yisong Y Wan, Richard A Flavell

Abstract readReview
In one paragraph

Review in Journal of molecular cell biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Mechanisms and Therapeutic Implications of EZH2 in Nasal Diseases.Clinical reviews in allergy & immunology · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Metabolic priming of GD2Molecular therapy. Methods & clinical development · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Acthar Gel Inhibits the Activation of CD4Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2023
    Article
  18. Article
  19. Harnessing Biomaterials for Immunomodulatory-Driven Tissue Engineering.Regenerative engineering and translational medicine · 2023
    Review
  20. Review

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yisong Y WanDepartment of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, 27599, USA. wany@email.unc.edu
Richard A Flavell

Funding

Roles for TAK1 in T Cell Development, Function and TumorigenesisR00AI072956 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WAN, YISONG · 2009 to 2010
$498k
Roles for TAK1 in T cell development, function and tumorigenesisK99AI072956 · NIAID · YALE UNIVERSITY · PI WAN, YISONG · 2008 to 2008
$90k
Howard Hughes Medical InstituteNIAID NIH HHS K99 AI072956NIAID NIH HHS R00 AI072956
6 · The paper itself

Abstract

CD4 effector T cells, also called helper T (Th) cells, are the functional cells for executing immune functions. Balanced immune responses can only be achieved by proper regulation of the differentiation and function of Th cells. Dysregulated Th cell function often leads to inefficient clearance of pathogens and causes inflammatory diseases and autoimmunity. Since the establishment of the Th1-Th2 dogma in the 1980s, different lineages of effector T cells have been identified that not only promote but also suppress immune responses. Through years of collective efforts, much information was gained on the function and regulation of different subsets of Th cells. In this review, we attempt to sample the essence of what has been learnt in this field over the past two decades. We will discuss the classification and immunological functions of effector T cells, the determinants for effector T cell differentiation, as well as the relationship between different lineages of effector T cells.

Indexed as

AnimalsCD4-Positive T-LymphocytesCell LineageGene Expression ProfilingHumansTranscription FactorsTranscription Factors

Identifiers

PMID19482777
PMCPMC2841031

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.